Pembrolizumab-induced sarcoid granulomatous panniculitis and bullous pemphigoid in a single patient

Key Clinical Message Pembrolizumab is an immune checkpoint inhibitor with antitumor activity in other organ malignancies. We present this case demonstrating multiple inflammatory adverse events associated with Pembrolizumab (in a single patient), in order to increase awareness and facilitate earlier identification of the wide-ranging cutaneous side effects associated with immunotherapy.